Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

Markets rejoice over positive COVID-19 vaccine data- Monday Review, November 16

Markets rejoice over positive COVID-19 vaccine data- Monday Review, November 16

Asian markets high over signing the world's largest regional free-trade partnership

The US

Moderna's positive data made the benchmarks close at record highs, even after the US reported more than 11 million cases. USA30 rose 1.60%, while USA500 went up 1.17%. TECH100 added 0.80%.

Gold climbed 0.3% to $1,891.60 per ounce.

Crude oil settled up at $41.34 per barrel, while Brent ended the day 2.4% higher at $43.82.

Asia and Australia

The markets surged after fifteen counties, including China, Japan, and Australia, signed the Regional Comprehensive Economic Partnership trade deal. The deal aims to liberalize trading between the countries.

Japan225 surged 2.05%, hitting a five-year high.

HongKong45 was up 0.63%.

Down under, Australia200gained 1.23%.

USD/JPY lost 0.07% to 104.55.

Europe

The stocks ended the day in the green, being moved by Moderna's data regarding its experimental COVID-19 vaccine. Germany30 and UK100 each closed 0.7% higher. France40 climbed 0.9%.

EUR/USD traded at 1.869 after it gained 0.3%.

Read here all about Moderna’s drug!

Sources: investing.com, reuters.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com